active agents being such that the combination thereof is therapeutically-effective in the treatment of said proliferative disorder.

The disclosure also relates to a kit comprising (i) first component comprising, as an active agent, one or more oral unit dosage forms of vemurafenib; and (ii) a second component comprising, as an active agent, one or more oral or injectable unit dosage forms of an MDM2 inhibitor. In a second aspect, there is provided a kit comprising: (i) a first component comprising, as an active agent, one or more unit dosage forms of vemurafenib, or a pharmaceutically-acceptable salt thereof; and (ii) a second component which comprises, as an active agent, one or more unit dosage forms of Compound III, or a pharmaceutically acceptable salt thereof.

The present disclosure further relates to a pharmaceutical composition comprising a therapeutically effective amount of (i) vemurafenib, or a pharmaceutically-acceptable salt thereof, and (ii) an MDM2 inhibitor.

In addition, the present disclosure relates to the use of vemurafenib, or a pharmaceutically-acceptable salt thereof, and an MDM2 inhibitor for the treatment of a proliferative disorder.

The present disclosure further relates to the use of vemurafenib, or a pharmaceutically-acceptable salt thereof, and an MDM2 inhibitor for the preparation of a medicament for the treatment of a proliferative disorder.

In a third aspect, there is provided the use of vemurafenib, or a pharmaceutically-acceptable salt thereof, and an MDM2 inhibitor, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer.

Brief Description of the Drawings

Figure 1 illustrates the antitumor activity, as demonstrated by the change in mean tumor volume over time, of vemurafenib monotherapy, Compound II and Compound III monotherapy, and vemurafenib plus Compound II and vemurafenib plus Compound III combination therapy.

Detailed Description of the Invention

As used herein, the terms “antineoplastic” or “antitumor” mean inhibiting the development, maturation or proliferation of malignant cells.

As used herein, the terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell


14. A kit comprising: (i) a first component comprising, as an active agent, one or more unit dosage forms of vemurafenib, or a pharmaceutically-acceptable salt thereof; and (ii) a second component which comprises, as an active agent, one or more unit dosage forms of Compound III, or a pharmaceutically acceptable salt thereof.

15. A kit according to claim 14, for use in the treatment of a proliferative disorder, preferably cancer selected from the group consisting of colorectal cancer, melanoma, sarcoma and thyroid cancer and wherein said cancer involves a tumor comprising b-Raf having the V600E mutation.

16. The use of vemurafenib, or a pharmaceutically-acceptable salt thereof, and an MDM2 inhibitor, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of ~~a proliferative disorder, in particular~~ cancer~~, more particularly cancer selected from the group consisting of colorectal cancer, melanoma, sarcoma and thyroid cancer and wherein said cancer involves a tumor comprising b-Raf having the V600E mutation~~.

17. The use according to claim 16, wherein the cancer is selected from the group consisting of colorectal cancer, melanoma, sarcoma and thyroid cancer and wherein said cancer involves a tumor comprising b-Raf having the V600E mutation.

~~17~~18. The use according to claim 16 or 17, wherein the MDM2 inhibitor is Compound (III)



(III).

***